Product Name: Prinoxodan (RGW2938)
Cat. No.: GC32503

Chemical Properties

- **Cas No.**: 111786-07-3
- **Chemical Name**: N/A
- **Canonical SMILES**: O=C1NC2=C(C=C3=N[N](C(C3)=O)C=C2)CN1C
- **Formula**: \( \text{C}_{13}\text{H}_{13}\text{N}_{4}\text{O}_{2} \)
- **M.Wt**: 257.27
- **Solubility**: Soluble in DMSO
- **Storage**: Store at -20°C
- **General tips**: For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition
- Evaluation sample solution: ship with blue ice
- All other available size: ship with RT, or blue ice upon request.

Background

Prinoxodan (RGW2938) is a phosphodiesterase inhibitor.
Prinoxodan (RG W-2938) is an orally effective positive inotropic/vasodilator agent. Prinoxodan is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent examined in vitro in isolated guinea pig hearts; in the latter, Prinoxodan 5 nmol-5 μmol increases contractility in a dose-related fashion[2].

Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and decreasing arterial pressure while only slightly affecting HR[2].